Sunday, September 24, 2017 6:22:28 PM
Momentum, in all honesty the FDA should have no say in where a company chooses to get its financing. If you are suggesting that FDA would be prejudiced against NWBO because Linda made that comment about going alone, than you're actually supporting the idea that FDA has been influenced by BigPharma. However, I don't think that's the case. Linda has often talked about working closely with regulators, and at both annual meetings I attended, talked about how participants at the hospital level have made positive comments to them. I have gotten the impression that their relationship with regulators in all countries is good.
Think about this....what would happen in UK, Canada, and Germany if the FDA failed to approve DCVaxL in the face of overwhelming evidence? They would probably go ahead and approve it in their own country, and they would talk and show how overwhelming the evidence is. Within a year, the FDA would be under investigation, perhaps, particularly if those countries start showing numbers that support efface you. What verybody seems to forget here is that we have 4 chances to be successful.so I think prejudice by FDA individual members can't happen with 3 other country regulators involved. They will force FDAs hand or make them look as prejudice as they would be if this happened. That's why Linda and co. Are gathering as many facts as possible. Just in case somebody or some bodies have been bought.
Just my 2 cents
Think about this....what would happen in UK, Canada, and Germany if the FDA failed to approve DCVaxL in the face of overwhelming evidence? They would probably go ahead and approve it in their own country, and they would talk and show how overwhelming the evidence is. Within a year, the FDA would be under investigation, perhaps, particularly if those countries start showing numbers that support efface you. What verybody seems to forget here is that we have 4 chances to be successful.so I think prejudice by FDA individual members can't happen with 3 other country regulators involved. They will force FDAs hand or make them look as prejudice as they would be if this happened. That's why Linda and co. Are gathering as many facts as possible. Just in case somebody or some bodies have been bought.
Just my 2 cents
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
